Theratechnologies Inc. (THTX)

NASDAQ: THTX · IEX Real-Time Price · USD
2.46
0.02 (0.82%)
May 25, 2022 4:00 PM EDT - Market closed
Market Cap235.47M
Revenue (ttm)56.99M
Net Income (ttm)-27.21M
Shares Out95.72M
EPS (ttm)-0.37
PE Ration/a
Forward PE55.87
Dividendn/a
Ex-Dividend Daten/a
Volume19,532
Open2.45
Previous Close2.44
Day's Range2.41 - 2.48
52-Week Range2.05 - 4.46
Beta1.60
AnalystsBuy
Price Target4.35 (+76.8%)
Earnings DateJul 13, 2022

About THTX

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystr...

IndustryBiotechnology
Founded1993
CEOPaul Levesque
Employees87
Stock ExchangeNASDAQ
Ticker SymbolTHTX
Full Company Profile

Financial Performance

In 2021, THTX's revenue was 69.82 million, an increase of 5.71% compared to the previous year's 66.05 million. Losses were -31.73 million, 40.0% more than in 2020.

Financial numbers in millions CADFinancial Statements

Analyst Forecast

According to 12 analysts, the average rating for THTX stock is "Buy." The 12-month stock price forecast is 4.35, which is an increase of 76.83% from the latest price.

Price Target
$4.35
(76.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Appointments in Conjunction With Theratechnologies Annual Meeting

MONTREAL, May 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercializ...

2 weeks ago - GlobeNewsWire

Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies

MONTREAL, May 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercializ...

2 weeks ago - GlobeNewsWire

THERATECHNOLOGIES TO FOCUS ITS COMMERCIALIZATION ACTIVITIES ON THE NORTH AMERICAN TERRITORY

MONTREAL , April 27, 2022 /PRNewswire/ - Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of i...

4 weeks ago - PRNewsWire

Theratechnologies to Present at Bloom Burton & Co. Healthcare Investor Conference 2022

Presentation time starts on Tuesday, May 3rd at 1:30PM ET Presentation time starts on Tuesday, May 3rd at 1:30PM ET

1 month ago - GlobeNewsWire

Theratechnologies Reports Financial Results for First Quarter Fiscal 2022 and Provides Business Update

- Q1 2022 consolidated sales grew 20%, supported by 35% growth in EGRIFTA SV ® sales

1 month ago - GlobeNewsWire

Theratechnologies Presents New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer ...

Two Additional Preclinical Proof-of-concept Posters in Ovarian and Metastatic Lung Cancer Models Also Presented at the Meeting

1 month ago - GlobeNewsWire

Theratechnologies to Announce Financial Results for Its First Quarter 2022

MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovati...

1 month ago - GlobeNewsWire

Theratechnologies to Present Three Posters at AACR Including New In Vivo TH1902 Preclinical Data Demonstrating Tumor ...

MONTREAL, March 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercial...

2 months ago - GlobeNewsWire

Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update

- FY2021 consolidated sales grew 5.7% supported by strong EGRIFTA SV ® sales

3 months ago - GlobeNewsWire

Theratechnologies Presents Results From Trogarzo® IV Push Administration Study at CROI 2022

MONTREAL, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commerciali...

3 months ago - GlobeNewsWire

Theratechnologies Strengthens Global Commercial Capabilities by Launching Internal Field Force

- Top Performing U.S. Based Key Account Managers, Medical Sales Liaisons, and Community Liaisons to join Theratechnologies' from its current partner contract sales organization

3 months ago - GlobeNewsWire

Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021

MONTREAL, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovativ...

3 months ago - GlobeNewsWire

Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo...

sBLA submission with FDA follows on the back of recently announced positive TMB-302 study results sBLA submission with FDA follows on the back of recently announced positive TMB-302 study results

5 months ago - GlobeNewsWire

Theratechnologies Named Recipient of the 2021 ADRIQ Innovation Award in the "Life Sciences" Category

MONTREAL, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization ...

5 months ago - GlobeNewsWire

Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Exte...

MONTREAL , Nov. 23, 2021 /PRNewswire/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercializati...

6 months ago - PRNewsWire

Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021

MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

6 months ago - GlobeNewsWire

Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resi...

MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

7 months ago - GlobeNewsWire

Theratechnologies Announces Publication in Frontiers in Oncology Journal Highlighting SORT1+ Technology™ for Targetin...

MONTREAL, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization ...

7 months ago - GlobeNewsWire

Theratechnologies Q3 Earnings Lags Consensus As Trogarzo Sales Decline

Theratechnologies Inc (NASDAQ: THTX) reported Q3 sales of $17.85 million, +27% Y/Y propelled by higher Egrifta sales of $11.22 million, +64%. The revenue missed the consensus of $19.66 million.

7 months ago - Benzinga

Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2021 and Provides Business Update

- Q3 FY2021 consolidated sales grow 27% over Q3 FY2020 –

7 months ago - GlobeNewsWire

Theratechnologies to Present at the H.C. Wainwright 5th Annual Nash Investor Conference

MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovativ...

7 months ago - GlobeNewsWire

Theratechnologies to Announce Financial Results for Its Third Quarter Fiscal 2021

MONTREAL, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovati...

7 months ago - GlobeNewsWire

Theratechnologies' IV Push Form Of HIV Treatment At Par With IV Infusion

Theratechnologies Inc (NASDAQ: THTX) has announced results from a study evaluating an intravenous (IV) push form of Trogarzo (ibalizumab-uiyk) for HIV-1 infection. The TMB-302 study was conducted by the...

8 months ago - Benzinga

Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study

- TMB-302 study results demonstrate that there was no difference in pharmacokinetics between IV Push and IV Infusion -

8 months ago - GlobeNewsWire

Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021

MONTREAL, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovati...

8 months ago - GlobeNewsWire